News Agency
Men's Weekly

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

  • Written by PR Newswire

CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2 trial of the highly selective oral GLP-1 agonist RGT-075 is initiated in adults with...

Read more: Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

Gender-Inclusive Lash Treatments: Breaking Beauty Norms

Beauty is no longer defined by traditional gender standards, and the lash industry is evolving to reflect that.  In 2026, more clients of all genders are seeking lash lifts, tints, and extensions that enhance their natural features while respecting individual style... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion